Ovarian hyperstimulation syndrome

Gynaecologia et Perinatologia

Volumn 13, Issue 2, 2004, Pages 62-68

  Kasum, Miro ^a,b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Ovarian hyperstimulation syndrome; Ovaries; Stimulation

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; CHORIONIC GONADOTROPIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; GONADORELIN AGONIST; HEPARIN; METFORMIN; METHYLPREDNISOLONE; PENTOXIFYLLINE; PLASMA SUBSTITUTE; PROGESTERONE; RECOMBINANT LUTEINIZING HORMONE; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASOACTIVE AGENT;

AGE; ANOVULATION; BED REST; CLINICAL TRIAL; CRYOPRESERVATION; CRYSTALLOID; DISEASE CLASSIFICATION; DISEASE EXACERBATION; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; HYPOTHYROIDISM; INCIDENCE; LEAN BODY WEIGHT; MACROMOLECULE; META ANALYSIS; OLIGOMENORRHEA; OVARY DISEASE; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PARACENTESIS; PATHOGENESIS; REVIEW; RISK FACTOR; SHOCK; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS;

EID: 3442875570     PISSN: 13300091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-61.
2. Ciglar S. Bradna neplodnost. U: Šimunic V. i sur. Ginekologija. Zagreb: Naklada Ljevak, 2001:349-57.
3. Eldar-Geva T, Calderon I, Healy D. Endocrinology of IVF. In: Handbook of in vitro fertilization. Boca Roton-London-New York: CRC Press, 2000:35-66.
4. Lunenfeld B, Maschiach S, Blankstein J. Induction of ovulation with gonadotrophins. In: Shearman RP. Clinical reproductive endocrinology. Edinburgh-London-Melbourne: Churchill Livingstone, 1985, 523-33.
5. Rabau E, Serr DM, David A, Maschiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol 1967;98:92-8.
6. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255-68.
7. Golan A, Ron-El R, Herman A, Soffer Y, Weinraab Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;6:430-40.
8. Tal J, Paz B, Samberg I, Lazarov N, Sharf M. Ultrasonographic and clinical correlates of menotropins. In: Blankenstein J, Maschiach S, Lunenfeld B (eds.). Induction of ovulation and in vitro fertilization. Chicago: Yearbook Medical Publishers, 1986:122-8.
9. Blankenstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987;47:597-602.
10. Haning RV Jr, Austin CV, Carlson IH, Kuzman DL, Shapiro SS, Zweibel WJ. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 1983;40:31-6.
11. Lewis CG, Wurnes GM, Wang X, Mathews CD. Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. Fertil Steril 1990;53:1097-9.
12. Tortoriello DV, Mc Govern PG, Colon JM. Coasting does not adversly affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998;69:454-60.
13. Fluker MR, Hooper WM, Yuzpe AA. Withholding gonadotropins (»coasting«) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization - embryo transfer cycles. Fertil Steril 1999;71:294-301.
14. Asch RH, Li H, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991;6:1395-99.
15. Salat-Baroux J, Alvarez S, Antione JM. Treatment of hyperstimulation syndrome during in-vitro fertilization. Hum Reprod 1990;5:36-9.
16. Schenker JG. Prevention and treatment of ovarian hyperstimulation syndrome. Hum Reprod 1993;8:653-9.
17. Morris RS, Paulson RJ, Herman A. Serum estradiol concentration and ovarian hyperstimulation syndrome. Hum Reprod 1995;9:811-14.
18. Tummon IS, Henig I, Radwanska E, Binor Z, Rawlins W. Persistent ovarian cyst following administration of human menopausal and chorionic gonadotropins: an attenuated form of ovarian hyperstimulation syndrome. Fertil Steril 1988;49:244-8.
19. Mathur RS, Akande AV, Keay SD, Hund LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-8.
20. Tanbo T, Dale PO, Kjekshus E, Haug E, Abyholm T. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone suppression in polycystic ovary syndrome. Fertil Steril 1990;53:798-803.
21. Dale PO, Tanbo T, Haug E, Abyholm T. Polycystic ovary syndrome: low dose follicle stimulating hormone administration in previous hyper-responsive patients. Hum Reprod 1992;7:1085-9.
22. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH analogues for IVF and related procedures. Hum Reprod 1992;7:320-7.
23. Forman RG, Frydman R, Egan D, Rose C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and proposal for prevention. Fertil Steril 1990;53:502-9.
24. Asch RH, Ivery G, Goldsman G, Frederick J, Stone SC, Balcameda JP. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993;8:1015-20.
25. Mathur RS, Joels LA, Akande AV, Jenkins JM. The prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1996;103:740-6.
26. Delvigne A, Rosenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2002;47:211-26.
27. Harada IM, Iwabe T, Tanikawa M, Terakawa N. Cytokine levels in a patient with severe ovarian hyperstimulation syndrome and after ultrafiltration and reinfusion of ascitic fluid. J Assist Reprod Genet 2000;17:118-20.
28. Chen CD, Chen HV, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:1037-42.
29. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-8.
30. Wang Q, Yang K, Yang C, Zhan B, Yang R. The predictive role of vascular endothelial growth factor and estradiol in infertile patients with ovarian hyperstimulation syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;34:565-8.
31. Ohba T, Ujioka T, Ishikawa K, Tanaka N, Okamura H. Ovarian hyperstimulation syndrome. Mol Cell Endocrinol 2003;202:47-52.
32. Yang TH, Horng SG, Chang CL et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-8.
33. Albert C, Garrido N, Mercader A, Rao CBV, Remohi J, Pell A. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation sydrome. Mol Hum Reprod 2002;8:409-18.
34. Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increase ovarian vascular endothelial growth factor and its receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003;68:2164-71.
35. Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induce vascular permeability in hyperstimulated rats, and this effect prevented by receptor blockade. Endocrinology 2002;143:4339-48.
36. Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome highly responsive women undergoing assisted conception. Fertil Steril 2002;78:1154-8.
37. Mc Elhinney B, Ardill J, Caldwell C, Lloyd F, Mc Clure N. Variations in serum vascular endothelial growth factor binding profiles and the development ovarian hyperstimulation syndrome. Fertil Steril 2002;78:286-90.
38. Mc Elhinney B, Ardill J, Caldwell C, Lloyd F, Mc Clure N. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 2002;17:1548-53.
39. Navot D, Margalioth EJ, Laufer N. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome. Fertil Steril 1987;48:57-61.
40. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 1992;9:429-38.
41. Balasch J, Arroyo V, Carmona F, Liach J, Jimenez W, Pare JCV, Vanrell JA. Severe hyperstimulation syndrome: role of peripheral dilatation. Fertil Steril 1987;56:1077-83.
42. Teruel MJ, Carbonell JF, Parilla JJ, Abada L, Hernandez I. Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabit. Fertil Steril 2002;77:1056-60.
43. Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2003;80:86-90.
44. Delvigne A, Kostyla K, Marillo D, Van Hoeck J, Rozenberg S. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2003;48:25-31.
45. Shoham Z, Schlachter M, Loumaye E et al. The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995;64:237-51.
46. Emperaire JC, Ruffie A. Triggering ovulation with endogenous luteinizing hormone to prevent the ovarian hyperstimulation syndrome. Hum Reprod 1991;6:506-10.
47. Delvigne A, Rozenberg S. Preventive attitudes do avoid OHSS in IVF. Hum Reprod 2001;16:2491-5.
48. Tay CC. Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum Fertil 2002;5:35-7.
49. Tomaževie T, Vrtovec M. Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. J Assist Reprod Genet 1996;13:282-6.
50. Egbare PE, Sharan M, Grudzinkas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized trial. Hum Reprod 1999;14:1421-25.
51. Shaker A, Zosmer A, Dean N. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention ovarian hyperstimulation syndrome. Fertil Steril 1996;65:992-6.
52. Queenan JT Jr, Veeck LL, Toner JP. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997;12:1573-6.
53. Kinget K, Nijs M, Cox AM et al. A novel approach for patients at risk for ovarian hyperstimulation syndrome: elective transfer of a single zona free blastocyste on day 5. Reprod Biomed Online 2002;4:51-5.
54. Araujo E Jr, Bernardini L, Frederick JL, Asch RH, Balcameda JP. Prospective randomised comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal phase support in assisted reproduction. J Assist Reprod Genet 1994;11:74-8.
55. McEhinney B, Ardill J, Caldwell C, McClure N. Preventing ovarian hyperstimulation syndrome by inhibiting the effects of vascular endothelial growth factor. J Reprod Med 2003;48:243-6.
56. Tan SL, Balen A, Hussein E, Cambell S, Jacobs HS. The use of glucocorticoids for the prevention of ovarian hyperstimulation syndrome: a prospective randomized study. Fertil Steril 1992;58:378-83.
57. Lainas T, Petsas G, Stavropoulous E, Iliadis G, Minaretzis D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 2002;78:529-33.
58. Visnova H, Ventruba P, Crha I, Zakova J. Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome. Česka Gynekol 2003;68:155-62.
59. Shoham Z, Wessman A, Barash A. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome of an in vitro fertilization program: a prospective, randomized, placebo controlled study. Fertil Steril 1994;62:137-42.
60. Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cohrane review. Hum Reprod 2002;17:3027-32.
61. Halme J, Toma SK, Talbert JM. A case of severe ovarian hyperstimulation syndrome in a healthy oocyte donor. Fertil Steril 1995;64:857-9.
62. Murkherjee T, Copperman AB, Sandler B. Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer. Fertil Steril 1995;64:641-3.
63. Moutos DM, Miller MM, Mahadevan MM. Bilateral internal jugular venous thrombosis complicating severe ovarian hyperstimulation syndrome after prophylactic albumin administration. Fertil Steril 1997;68;174-6.
64. Ben-Chetrit A, Eldar-Geva T, Gal M et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 2001;16:1880-4.
65. Berker B, Demirel C, Satiroglu H. Internal jugular vein thrombosis as a late complication of ovarian hyperstimulation syndrome in an ICSI patient. Arch Gynecol Obstet 2003 (in print).